Smith and Nephew is a mid-cap United Kingdom medical-technology group that just proved it can defend profit after missing its own growth script. Two quarters into the RISE plan, launched at the December capital-markets day, management cut full-year underlying revenue growth from around six percent to around four percent. Trading profit, free cash flow, and adjusted return on invested capital guides stay intact only because another fifty million of efficiency savings appeared. The investment case now turns on whether that cost machine is a durable operating system or a one-year substitute for the volume RISE still needs.
The tension sits in the mix. Sports Medicine and ENT delivered first-half revenue of $1,017 million. That unit remains the only franchise compounding at a high-single-digit underlying rate and expanding trading margin on operating leverage. Orthopaedics and Advanced Wound Bioactives did the opposite. United States knee implants fell again, and the January skin-substitute reimbursement reset plus a soft SANTYL quarter pulled Wound Bioactives down at a double-digit clip in the second quarter. Integrity Orthopaedics, closed in January, diluted first-half trading profit even as the shoulder-repair offer improved.
Second-quarter revenue was $1,597 million, only a modest underlying rise. Management still holds the roughly $1.3 billion trading-profit guide and the $800 million free-cash-flow guide. Can United States knees and Wound Bioactives stabilize in the second half, or does the extra savings round become the entire profit story?